Cristina Pastorino
Genoa, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessment.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: February 05, 2026
Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR.
Journal: Frontiers in pharmacology
Published: July 07, 2025
In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators.
Journal: British journal of pharmacology
Published: March 14, 2025
Target Identification with Live-Cell Photoaffinity Labeling and Mechanism of Action Elucidation of ARN23765, a Highly Potent CFTR Corrector.
Journal: Journal of medicinal chemistry
Published: February 10, 2025
Pharmacological rescue of the G85E CFTR variant by preclinical and approved modulators.
Journal: Frontiers in pharmacology
Published: September 10, 2024
Clinical Consequences and Functional Impact of the Rare S737F CFTR Variant and Its Responsiveness to CFTR Modulators.
Journal: International journal of molecular sciences
Published: February 27, 2023
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes.
Journal: Cells
Published: November 04, 2022
Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell background.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: September 08, 2022
Targeting of Ubiquitin E3 Ligase RNF5 as a Novel Therapeutic Strategy in Neuroectodermal Tumors.
Journal: Cancers
Published: March 04, 2022
The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs.
Journal: International journal of molecular sciences
Published: February 20, 2022
Journey on VX-809-Based Hybrid Derivatives towards Drug-like F508del-CFTR Correctors: From Molecular Modeling to Chemical Synthesis and Biological Assays.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: February 01, 2022
Last Updated: 09/26/2026